2 September 2010

Lookers

STRONG BUY

21/03/2005

Motor retailer Lookers accelerated higher on another set of record numbers to December. Bossed by chief executive Ken Surgenor and finance director David Dyson, Lookers reached a significant milestone last year, lifting turnover comfortably past £1bn for the first time. The top line grew by 14%, profits before tax sped up 89% to £26.5m and the total payout lifted 10% to 12.1p. On the franchised car retailing side, Lookers fostered and expanded its ties with manufacturers, buying a number of dealerships including the Volkswagen franchise for Northallerton and Darlington, and Saab in Chester. Significantly, the company also boosted its presence in the 'steadier, higher-margin' car parts after-market with the acquisition of FPS Distribution. Post year-end, Lookers announced the addition of Bristol Trade Centre, the biggest used car supermarket in the south-west of England, for £8.5m. Even though industry analysts are forecasting a slight fall in new car registrations in 2005, Surgenor and Dyson point out demand for new cars remains healthy, having exceeded 2.4m units in every year since 2001. For December 2005, shop broker Numis is leaving forecasts unchanged following a small upgrade at the end of January. Investors can expects pre-tax profits of £18.2m and earnings of 36.6p, before a rise to £20m and 40p EPS for 2006. Forward p/e ratios of 9.1 and 8.3 look great value for Lookers, which is growing in prestige. Strong buy.

Sector: Automobiles & Parts

Companies: Lookers

Market cap: £116.7m

PE Forecast: 9.1

Share price: 333.5p

Subscribe today


More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.

Subscribe today and save 50%

VCT Report 2010

VCT Report 2010 uncovers the money available

for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted

company.

Order VCT Report 2010 today using this online form

Cash Shells Directory 2010

A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.

Coverage of AIM, techMARK and PLUS Markets

Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.

Take control of your investments

A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.

The Financial Times Guide to Personal Tax

is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.

The AIM Guide Spring 2010

The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).

A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!

Share recommendations and small-cap stock picks

Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.

Popular Recommendations

Latest Recommendations

Delcam 01/09/2010

Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.

Antisoma 01/09/2010

Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.

GW Pharmaceuticals 31/08/2010

GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.

More Recommendations

Sectors

Vitesse Media Events